生物科技公司Personalis宣布，其Next Personal®检测产品再次获得一项美国联邦医疗保险的覆盖决定。这是该产品获得的第四项医保覆盖决定，标志着其应用范围将进一步扩大至乳腺癌患者的术前治疗监测领域。此次覆盖决定的落地，意味着更多符合条件的乳腺癌患者在接受术前治疗时，能够通过该检测进行疗效监测与评估。
生物科技公司Personalis宣布，其Next Personal®检测产品再次获得一项美国联邦医疗保险的覆盖决定。这是该产品获得的第四项医保覆盖决定，标志着其应用范围将进一步扩大至乳腺癌患者的术前治疗监测领域。此次覆盖决定的落地，意味着更多符合条件的乳腺癌患者在接受术前治疗时，能够通过该检测进行疗效监测与评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.